Updates in Bispecific Antibodies for Heavily Pretreated Relapsed/Refractory Multiple Myeloma: Current and Emerging Targets
This Virtual Preceptorship invites learners to explore the mechanisms of bispecific antibodies in the management of relapsed/refractory multiple myeloma. Novel bispecific antibodies simultaneously target CD3 on immune T cells and a target on malignant B cells, such as BCMA. By guiding T cells to malignant myeloma cells, bispecific antibodies enable the precise immune attack of malignant cells. In the process of immune attack, bispecific antibodies may trigger adverse events that require careful monitoring and multidisciplinary management. In this virtual reality program, clinicians will gain perspectives on both mechanisms and safe use of bispecific antibodies in patients with relapsed/refractory multiple myeloma.
RELEASED DATE: January 29, 2025
EXPIRATION DATE: January 29, 2026
Updates in Antibody-Drug Conjugate Therapy for Breast Cancer: Focusing on TROP2-Directed Therapy
This Grand Rounds program will help you understand the biology of TROP2 in breast cancer; examine the rationale for use of TROP2-directed antibody-drug conjugates (ADCs) in breast cancer; recognize adverse effects most commonly associated with ADCs and best practices for their prevention, mitigation, and management; and formulate strategies for integrating TROP2-directed ADCs into breast cancer treatment algorithms. This interactive program combines didactic instruction with case-based discussions and illustrative animations.
RELEASED DATE: October 30, 2024
EXPIRATION DATE: October 30, 2025
Updates for VA Clinicians in the Use of Bispecific Antibodies Across Later-Line Non-Hodgkin’s Lymphomas: Summarizing Current Efficacy and Safety Data (Podcasts)
Non-Hodgkin’s Lymphoma accounts for about 4% of cancers in the US. It also affects the VA population and is majorly caused due to exposure to toxic substances. In this podcast, we will discuss the current treatments, adverse events and management of VA NHL patients. We will cover diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL).
RELEASED DATE: January 25, 2024
EXPIRATION DATE: January 25, 2025
Updates for the Multidisciplinary Oncology Care Team on the Biology, Clinical Data, and Safety of HER3-Targeted Agents in Lung Cancer
This enduring activity is designed to meet the educational needs of healthcare practitioners to ensure confidence in the management of patients with HER3-overexpressing lung cancer. The program will address the biologic and clinical aspects of HER3 in advanced and EGFR-resistant NSCLC, and present the latest clinical trial data from current and ongoing trials of HER3-targeted antibodies in the management of NSCLC. The program will also evaluate the roles of multidisciplinary team members in the monitoring and management of treatment-related adverse events associated with HER3-targeted therapies.
RELEASED DATE: December 12, 2024
EXPIRATION DATE: December 12, 2025
The Latest Approaches to the Care of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas Including the Use of Bispecific Antibodies
This CME activity will provide hematologists and oncologists with practical, case-based insights into the management of patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma, with a special focus on follicular lymphoma (R/R FL). Expert faculty will review prognostic tools and clinical features, including early relapse, to guide risk stratification and inform treatment planning. The program will highlight the role of bispecific antibody therapies, with an emphasis on integrating clinical trial data into personalized care strategies. Special attention will be given to proactive recognition, grading, and management of toxicities, particularly cytokine release syndrome, as well as best practices in infection prophylaxis and monitoring. Through didactic discussion, illustrative case study, and whiteboard animation, learners will gain strategies to optimize outcomes and safely implement bispecific therapies for patients with R/R FL.
RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026
The ENCOMPASS Experience: The Management of Relapsed/Refractory Non-Hodgkins Lymphoma with Bispecific Antibodies
This enduring program encompasses the management of relapsed/refractory non-Hodgkins lymphoma (NHL) with a new class of therapy—bispecific antibodies. These novel and emerging agents redirect T-cells to attack CD20-positive NHL, resulting in immune-mediated clearance of malignant cells. To ensure safe use of these off-the-shelf therapies, this program will also review best practices for grading and management of potential adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
RELEASED DATE: January 24, 2025
EXPIRATION DATE: January 24, 2026
The ENCOMPASS Experience: Revolutionizing Non-Hodgkin Lymphoma Treatment With T-cell Redirecting Bispecific Antibodies in Relapsing/Refractory Disease
This enduring program is designed to address the management of relapsed/refractory non-Hodgkin lymphoma (NHL) with a new class of therapy—bispecific antibodies. These novel and emerging agents redirect T-cells to attack CD20-positive NHL, resulting in immune-mediated clearance of malignant cells. To ensure safe use of these off-the-shelf therapies, this program will also review best practices for grading and management of potential adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
RELEASED DATE: January 24, 2025
EXPIRATION DATE: January 24, 2026
The ENCOMPASS Experience: Incorporating Bispecific Antibodies into the care of Patients with Relapsed/Refractory Multiple Myeloma with an Emphasis on Managing Potential Adverse Events
This enduring program explores the need for novel treatment options and the mechanism of bispecific antibodies in the management of relapsed/refractory multiple myeloma. To ensure safe use of these agents, learners will also revisit strategies for both grading and management of potential adverse events associated with bispecific antibodies, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.
RELEASED DATE: January 24, 2025
EXPIRATION DATE: January 24, 2026
The ACTIVATE Initiative:
Checkpoint Inhibition Combinations in Melanoma: Evaluating Current Therapies and the Role of Anti-LAG3 Antibodies
These podcasts are designed to help healthcare professionals assess the relationship between checkpoint inhibition and immunopathology in advanced melanoma, update them on the latest clinical data with anti-LAG3 antibody combinations in advanced melanoma, and provide strategies to optimize the safety of combination immunotherapy approaches in advanced melanoma. Additionally, healthcare professionals will be able to understand the importance of patient advocacy as we converse with a patient about their cancer diagnosis and treatment.
RELEASED DATE: April 21, 2023
EXPIRATION DATE: April 21, 2024
Payer Considerations in NHL: Updates in the Use of Bispecific Antibodies in DLBCL and FL
This innovative online educational programming is designed to meet the educational needs of payers, clinical pharmacists, medical oncologists, hematologists, nurse practitioners, and other members of the multi-disciplinary oncology care team. Using a combination of slides, infographic data, and a whiteboard animation, we aim to help learners understand the importance of bispecific antibodies including interpretation of their safety and efficacy data, in addressing previously unmet needs in the management of DLBCL and FL. This will help to inform coverage for patients with DLBCL and FL. Additionally, the goal is to familiarize learners with potential adverse events associated with the use of bispecific antibodies and discuss strategies for their monitoring and management in clinical practice.
RELEASED DATE: April 30, 2025
EXPIRATION DATE: May 16, 2026